EyeOP1
Commercial- Indications
- Glaucoma
Company intelligence / Profile preview
The company's flagship product, EyeOP1, uses high-intensity focused ultrasound to non-invasively treat glaucoma by targeting the ciliary body. Clinical experience includes over 7,000 treated patients worldwide with strong safety and efficacy profiles. The procedure can be performed quickly (<5 minutes), repeated as needed, and offers an alternative for patients not controlled by conventional therapies. The technology has received CE Mark approval in Europe and CFDA approval in China. Published results indicate good tolerance with minimal side effects across a broad spectrum of glaucoma severity.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Eye Tech Care.